Treatment with VASH1 may be effective for chemotherapy‐resistant ovarian cancer and may prevent adverse events of anti‐VEGF antibody therapy, such as hypertension and proteinuria, because VASH1 is usually induced as negative feedback regulator under conditions of abnormal angiogenesis, such as that within the context of tumorigenesis. This evidence concerns the gene VEGFA and ovarian carcinoma.